Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "Hematology"
DOI: 10.1080/10245332.2018.1509461
Abstract: ABSTRACT Objectives: Chemoimmunotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with rituximab (R-CHOP) is currently the first-line therapy for diffuse large B-cell lymphoma (DLBCL). However, management of elderly patients is challenging and often requires dose… read more here.
Keywords: cyclophosphamide doxorubicin; reduced dose; vincristine prednisolone; doxorubicin vincristine ... See more keywords
Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone
Sign Up to like & getrecommendations! Published in 2018 at "Oncology Letters"
DOI: 10.3892/ol.2018.7774
Abstract: Treatment with rituximab plus a regimen of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) for patients with diffuse large B-cell lymphoma (DLBCL) has proven efficacy in clinical trials. The present study investigated its application in clinical… read more here.
Keywords: cyclophosphamide doxorubicin; rituximab plus; vincristine prednisolone; diffuse large ... See more keywords